Last updated: 2026-09-04 13:04:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Annovis Bio, Inc. (ANVS) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NYSE. The stock is currently priced at $1,40, with a market capitalisation of $72,43M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1,32 to $5,50. This page covers its latest market performance, valuation, price trends and company information.
$72,43M | |
$1,41 | |
$132,00 | |
$1,11 | |
$1,38 | |
35,45K | |
-- | |
-- | |
$5,50 | |
$1,32 | |
-- | |
-- |
Annovis Bio, Inc. (ANVS) last closed at $1,38 as of 2026-09-04 12:46:39, unchanged from the previous close of $1,38.
During the latest regular trading session, ANVS traded between $1,11 and $132,00, with a volume of 35,45K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Annovis Bio, Inc. (ANVS) moved from $1,72 to $1,40, representing a decline of 18,60% ($0,32).
The stock traded between $1,32 and $1,83 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 1,38 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 1,9%
ANVS is currently trading at $1,40, placing it 1,9% of the way from its 52-week low of $1,32 to its 52-week high of $5,50. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 7 |
| Exchange | NYSE |
| Company Website |
Eligible investors can buy real shares of Annovis Bio, Inc. (ANVS) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.